Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review

doi:10.4239/wjd.v15.i8.1793

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1248)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

HTML

729

Figures (1-4)

134

Tables (1-1)

122

Sum=1014

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

126

Sum=158

Aug 15, 2024 (publication date) through Nov 27, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Diabetes. Aug 15, 2024; 15(8): 1793-1801
Published online Aug 15, 2024. doi: 10.4239/wjd.v15.i8.1793

Full Size Figure Download Figure

Figure 2 Preferred reporting items for systematic reviews and meta-analyses diagram for inclusion of studies discussing the adverse effects of teplizumab. ¹No automation tools used in record search.

Citation: Buddhavarapu V, Dhillon G, Grewal H, Sharma P, Kashyap R, Surani S. Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review. World J Diabetes 2024; 15(8): 1793-1801
URL: https://www.wjgnet.com/1948-9358/full/v15/i8/1793.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i8.1793